LDN-192960

• Description:

  LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  DYRK; Haspin Kinase

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/LDN-192960.html

• Purity:

  99.58

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  NCCCSC1=C(C=C(OC)C=C2)C2=NC3=CC=C(OC)C=C31

• Molecular Formula:

  C18H20N2O2S

• Molecular Weight:

  328.43

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Cuny GD, et al. Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20 (12) :3491-4.|[2]Katrin Kestav, et al. Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin. Curr Med Chem. 2017;24 (21) :2276-2293.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  DYRK1; DYRK2

• Citation 01:

  Universidad de Córdoba. 2023 Sep 11.|Bioorg Chem. 2024 Jun:147:107412.

• CAS Number:

  [184582-62-5]